A new staggered DiD method separates direct and spillover effects by comparing units with identical exposure profiles and estimating spillovers from never‑treated units; applied to Community Health Centers, spillovers explain a substantial share of the observed decline in older‑adult mortality, and ignoring them biases standard DiD estimates.

Main Finding

The paper develops a difference‑in‑differences (DID) framework for staggered policy adoption that explicitly allows for network spillovers. It (i) defines three cohort-and-event-time causal objects that separate own-adoption and spillover components — the dynamic switching effect (DSE), the control‑state spillover effect (CSE), and their sum, the dynamic total effect (DTE) — (ii) gives identification conditions for each object using a prespecified exposure mapping and never‑treated units as a source for spillover learning, and (iii) proposes estimators and spatial HAC inference. Monte Carlo evidence shows standard DID that ignores spillovers can miss the rollout’s total effect, while the proposed estimators have small bias and good coverage. An application to Community Health Centers finds spillovers account for a substantial share of the effect on older‑adult mortality.

Key Points

• Problem setting
  • Staggered adoption with absorbing treatment; units can be affected by others’ adoptions (interference).
  • Standard SUTVA fails: treated vs. never‑treated does not equal exposed vs. unexposed.
• Exposure mapping
  • Spillovers summarized by a prespecified mapping Hit = b(eHit(G−i)), where eHit = Σj≠i wij ψ(t − Gj). Mapping requires researcher choice of weights wij, time kernel ψ(·), and coarsening b(·).
  • Maintained assumption: potential outcomes depend on (own adoption time Gi, exposure state Hit) only: Yit(G) = Yit(Gi, Hit).
• Target estimands (cohort g, event time l where t = g + l)
  • DSE(g,l) = E[Yi,t(g, Hit) − Yi,t(∞, Hit) | Gi = g]: effect of switching own adoption holding realized exposure fixed.
  • CSE(g,l) = E[Yi,t(∞, Hit) − Yi,t(∞, 0) | Gi = g]: untreated‑state spillover contrast averaged over the treated cohort’s exposure distribution.
  • DTE(g,l) = DSE(g,l) + CSE(g,l): total effect of realized rollout vs. pure control (untreated & zero exposure).
• Identification strategy
  • DSE identified by comparing treated cohort changes to never‑treated units that share the same baseline and target exposure states (conditional parallel trends).
  • CSE learned from exposure contrasts within never‑treated units (parallel trends within never‑treated) and transported to the treated cohort via a transportability assumption.
  • No nonparametric identification of the pure direct effect at zero exposure for treated units unless they are observed at zero exposure (support/overlap restriction).
• Estimation & inference
  • DSE estimator: saturated long‑difference comparison within retained cells (cells defined by covariates and baseline & target exposure states).
  • CSE estimator: fit untreated‑state spillover response in the never‑treated source sample; evaluate predicted contrast over treated cohort’s covariate–exposure distribution.
  • DTE obtained by summing DSE and CSE on the same admissible support.
  • Inference: stack estimating equations for DSE, CSE (and DTE) and compute spatial heteroskedasticity-and-autocorrelation-consistent (spatial HAC) covariance matrices to allow for network/spatial dependence.
• Empirical & simulation findings
  • Simulations: conventional DID that ignores spillovers can substantially misstate the rollout’s total effect; proposed estimators are approximately unbiased and CIs have near‑nominal coverage.
  • Application (Community Health Centers rollout): accounting for spillovers materially changes estimated effects; spillovers explain a substantial portion of the effect on older‑adult mortality relative to analyses that ignore interference.

Data & Methods

• Data structure
  • Panel of N units, t = 1,...,T. Own treatment status Dit ∈ {0,1} with absorbing adoption; adoption time Gi ∈ {2,...,T} ∪ {∞} (∞ = never treated).
  • Observed outcomes Yit = Yit(Gi, Hit) under Assumptions below.
• Exposure mapping (operationalization)
  • Raw exposure: eHit(G−i) = Σj≠i wij ϕ(t, Gj) with ϕ(t, Gj) = ψ(t − Gj) 1{t ≥ Gj}.
  • Coarsening: Hit = b(eHit) into a finite set H (contains 0).
  • Weights wij and kernel ψ(·) are prespecified by the researcher (choice encodes maintained interference structure).
• Core assumptions (summary)
  • Assumption 2.1: Reduced‑form potential outcomes depend only on (Gi, Hit): Yit(G) = Yit(Gi, Hit).
  • Assumption 3.1: No anticipation: pre‑baseline outcomes for cohort g equal untreated potential outcomes at realized exposure.
  • Assumption 3.2 (DSE parallel trends): conditional on baseline and target exposure states Sg,l i = (Hi,t0, Hi,t), and covariates Xd i, the change in untreated potential outcomes is equal for cohort g and never‑treated units.
  • Assumption 3.3 (CSE identification within never‑treated): within never‑treated units, trends for Yit(∞,0) conditional on covariates do not depend on current exposure Hit (permits using zero‑exposure never‑treated cells as counterfactual for exposed never‑treated cells).
  • Assumption 3.4 (Transportability): the untreated‑state spillover response r∞,t(x,h) learned in the never‑treated source sample equals the target cohort’s response rg,t(x,h) (allows evaluating CSE over treated cohort’s covariate–exposure distribution).
  • Support/overlap: never‑treated units must provide support for the exposure×covariate cells required by the identification (exposure states faced by treated cohorts must be represented among never‑treated).
• Estimators
  • DSE: within each retained cell (same Xd, same baseline & target exposure states), compute long‑difference saturated DID (treated cohort change minus never‑treated change).
  • CSE: estimate r∞,t(x,h) (untreated spillover response) from never‑treated units — e.g., regression of Yit(∞,h) − Yit(∞,0) on (x,h) — then take the expectation of the fitted contrast over the empirical distribution of (Xd, Hit) in cohort g.
  • DTE: post‑estimation sum DSE + CSE on the same admissible support.
• Inference
  • Stack moment/estimating equations for DSE and CSE across event times.
  • Use spatial HAC covariance estimators to account for spatial/network dependence and heteroskedasticity (following Leung 2022, Xu 2025).
• Validation
  • Monte Carlo: shows bias reduction and CI coverage improvement vs. naive DID that ignores spillovers.
  • Empirical example: mortality effects of Community Health Centers rollout; shows substantive share of effect attributable to estimated spillovers.

Implications for AI Economics

• Relevance to AI adoption studies
  • Many AI economics settings have staggered adoption (e.g., firms or regions adopt AI tools, data infrastructures, platform features over time) and network spillovers (supply‑chain links, labor market mobility, consumer networks, platform ecosystems). Ignoring interference in such designs can misattribute spillover-driven changes to direct adoption.
• What to measure when evaluating AI rollouts
  • Distinguish: (i) direct effect of own AI adoption holding neighbor exposures fixed (analogous to DSE), (ii) spillover effects that occur when own adoption is absent (CSE), and (iii) the realized total effect of the actual rollout (DTE). Policy conclusions can differ depending on which of these is targeted.
• Practical strategy for empirical work
  • Use an exposure mapping tailored to the AI setting (specify network weights wij, temporal decay ψ, and coarsening b). The mapping both defines estimands and imposes structure — choices should be defended substantively and tested in sensitivity analyses.
  • Learn spillovers from never‑treated units when available, but verify overlap: never‑treated units must span the exposure states experienced by treated cohorts.
  • Incorporate spatial/network‑robust inference (spatial HAC) because outcomes and residuals are likely correlated across linked units in AI networks.
• Cautions & limitations
  • The exposure mapping is a maintained (structural) assumption: omitted channels of interference not captured by the mapping produce biased estimates.
  • Transportability from never‑treated to treated cohorts is a strong assumption in many applied AI contexts (treated and never‑treated units may differ systematically in unobserved ways interacting with exposure).
  • Identification of the pure direct effect at zero exposure is generally not possible unless treated units are observed at zero exposure (support issue).
• Opportunities
  • The framework enables more credible welfare and counterfactual analyses of staggered AI policies where network effects matter (e.g., diffusion of productivity gains, labor reallocation, platform externalities).
  • Researchers can quantify how much of observed impact of an AI rollout is due to spillovers versus direct adoption — critical for targeting policy (subsidies, regulation, supporting complementary investments) and for extrapolating effects to other rollout scenarios.
  • The methodology suggests diagnostics and sensitivity checks (vary weights, kernels, coarsening thresholds; test overlap; compare with no‑spillover DID) that are particularly important in AI economics where network structure and spillover channels are complex.

Overall, the paper provides a principled DID toolkit for staggered adoption with interference — relevant for many AI economics evaluations — while highlighting the strong role of the researcher’s exposure mapping choices and support/transportability assumptions.